Pitcairn Co. Grows Position in Sanofi (NASDAQ:SNY)

Pitcairn Co. increased its position in Sanofi (NASDAQ:SNY) by 17.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,940 shares of the company’s stock after buying an additional 1,296 shares during the quarter. Pitcairn Co.’s holdings in Sanofi were worth $515,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC grew its holdings in Sanofi by 15.5% in the 3rd quarter. Kingsview Wealth Management LLC now owns 5,901 shares of the company’s stock worth $340,000 after acquiring an additional 794 shares during the last quarter. Cerity Partners LLC increased its holdings in Sanofi by 37.7% during the 3rd quarter. Cerity Partners LLC now owns 127,083 shares of the company’s stock valued at $7,324,000 after purchasing an additional 34,785 shares during the period. Meridian Wealth Management LLC raised its position in Sanofi by 13.3% during the 3rd quarter. Meridian Wealth Management LLC now owns 42,369 shares of the company’s stock valued at $2,442,000 after purchasing an additional 4,972 shares during the last quarter. Icon Wealth Advisors LLC lifted its holdings in Sanofi by 7,954.4% in the 3rd quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after buying an additional 289,144 shares during the period. Finally, Citigroup Inc. grew its position in shares of Sanofi by 2.5% in the 3rd quarter. Citigroup Inc. now owns 631,672 shares of the company’s stock worth $36,403,000 after buying an additional 15,348 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 0.1 %

NASDAQ SNY opened at $48.35 on Tuesday. The stock’s 50 day moving average is $53.52 and its 200 day moving average is $52.18. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $122.70 billion, a PE ratio of 24.67, a P/E/G ratio of 1.22 and a beta of 0.61. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the prior year, the firm earned $2.55 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. Research analysts forecast that Sanofi will post 4.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.